He's not a doctor, or an analyst but he tries to play one on the internet.
I have been investing in biotech for 25 years and typically despise and rail against the greedy, ignorant execs that run many biotech firms. It's so refreshing to be invested in a company run by intelligent, shareholder-friendly executives. Congrats and thanks to the EXAS execs for the great job they have done and continue to do for their shareholders. May God Bless them!
I think scripts will get a good bounce after the obesity conference and heading into the new year. We do need some good results in smoking cessation to put a dent in the short thesis at least in the short term.
Pasting from a recent MarketWatch article:
A new report by Allied Market Research entitled, "Nonalcoholic Steatohepatitis Market (Pipeline analysis, drug class and Geography) Global Size, Industry Analysis, Trends, Opportunities, Growth and Forecast, 2013 - 2020", indicates that the global nonalcoholic steatohepatitis (NASH) market would reach $1.6 billion by 2020 registering CAGR of 25.6% from 2014 to 2020. The high prevalence of Type II diabetes and obesity, which lead to NASH and other non-alcoholic fatty liver diseases (NAFLD), would boost market growth.
Spreading garbage. ZFGN's obesity drug is a joke, a commercial failure waiting to happen IMO.
I am still in that camp, he's not CEO material. He may be good at some things, but leading a commercial company, communicating with shareholders, maximizing valuation, financial markets are all Not strengths. Of course, if Jack moves to Chairman, we would get another money-sucking CEO in his place and still have to pay Jack waaaay too much, so it might be even worse. I would like to see Jack work for stock (he already gets plenty) and a low salary, then I might respect him more.
let's see the smoking trial results before getting too excited. If efficacy is even close, it will crush Chantix, but all we have is anecdotal evidence at this point.
I traded emails through the normal course of my business with an Eisai employee recently. I let the person know I was rooting for Belviq sales and a long suffering ARNA shareholder. The person said not to worry and mentioned if they get approval for smoking...Nothing earth shattering and this person is not an insider, or senior exec, but it was good to hear don't worry. I am still worrying, at least in the short run because I can't understand $3..ARNA.
well said, the data from the PR was not detailed, more to come next week, more time and likely additional studies to come until this translates into meaningful sales. We really need smoking to work to kill the shorts. Some additional country approvals would also help.
sure and the study was sponsored by WW and the makers of Q. Nice try shorty.
I have been investing in biotech for 25 years. Most of the CEO's are terrible. I am really impressed with the EXAS CEO, he has his act together, he's strong, well prepared, knows how to tell a story, he seems credible and rock solid. I wish my other biotech firms were as well managed at the top. Nice call!
TW has been the only ARNA bull, so I agree, it would be good to know what he is thinking. I suspect that like all of us he is hoping for some good smoking cessation results to bolster the case for his high price target. Maybe he will come down another $1 on the PT. I will take $10 any time in 2015 and be very happy, but not quite retired.
I sent an em to Craig late last week, no reply yet and he's usually fairly prompt and courteous. Hoping to hear JL is retiring to the BOD soon, but doubt it. Stock is really getting UGLY. Glad I sold some calls, wish I had sold many more. Where is the new IR guy??? I think he's hiding under JL's desk! I am thinking of a joke, but should probably not go there.
Good for you Jim. Are you or your group in touch with any BOD members that can get Jack out? I agree, the sooner the better, cash is burning; neither Jack nor his bean counter are right for their job job. And what the heck is ARNA paying Cindy to do in Switzerland?
Business decisions need to be made, cost cutting is needed, capital needs to be allocated properly. We need a turnaround specialist and potentially a sale. I'm not sure anyone would be interested in buying ARNA until they figure out a growth strategy/market for Belviq, or get a new product further along.
Jack has a grip on the Board, we need to loose that grip. Go to work!
Cut and paste from Fiercebiotech today:
Shire is quickly moving on after AbbVie's plot to buy the company for $55 billion fell apart last month, giving the Irish drugmaker a new lease on freedom and a $1.6 billion breakup fee for its trouble. Now CEO Flemming Ornskov, who has presided over 6 acquisitions in his brief tenure, is hinting at more deals to come, pointing to Shire's $4.5 billion deal for ViroPharma last year as a template for the future.
did the article name AF and provide any facts? I have seen this mentioned on other boards. Short criminals are all over this industry, would love to see them exposed and prosecuted finally.